HMGN — Hemagen Diagnostics Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for Hemagen Diagnostics, fiscal year end - September 30th, USD millions except per share, conversion factor applied.

	2008 September 30th	2009 September 30th	2010 September 30th	2011 September 30th	2012 September 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10KSB	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	6.38	5.42	5.22	5.14	4.04
Cost of Revenue
Gross Profit	2.77	2.07	2.36	1.96	1.61
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	6.26	5.77	4.98	5.61	4.48
Operating Profit	0.118	-0.348	0.236	-0.473	-0.438
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-0.244	-0.708	-0.067	-0.876	-0.907
Provision for Income Taxes
Net Income After Taxes	-0.373	-0.729	-0.156	-0.88	-0.907
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	0.428	-0.807	-0.156	-0.88	-0.907
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	0.428	-0.807	-0.156	-0.88	-0.907
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.025	-0.05	-0.011	-0.057	-0.058
Dividends per Share